Recent Updates
Recently added Catalysts
OM Negative Sentiment Score: 25/100

OUTSET MEDICAL ALERT: Bragar Eagel & Squire, P.C. is Investigating Outset Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Outset Medical, Inc. due to a class action complaint filed against the company. The lawsuit claims that Outset Medical's board breached their fiduciary duties by making false or misleading statements regarding the Tablo products. Allegations include unapproved marketing for certain indications and potential risks to revenue growth. Investors are encouraged to contact the law firm for further information or to discuss their rights in relation to this investigation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Lawsuit alleging misleading statements by Outset Medical's board.
  • Potential cessation of Tablo sales pending FDA approval raises concerns.
  • Defendants' positive statements about the company's prospects deemed misleading.
  • Concerns about insufficient sales team and processes for executing sales ramp.

Full Press Release Details

NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outset Medical, Inc. (NASDAQ: OM) on behalf of long-term stockholders following a class action complaint that was filed against Outset Medical on August 29, 2024 with a Class Period from August 1, 2022 to August 7, 2024. Our investigation concerns whether the board of directors of Outset Medical have breached their fiduciary duties to the company.
According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications approved by the United States Food and Drug Administration (“FDA”); (2) as a result, Outset Medical was reasonably likely to submit an additional 510(k) application for the Tablo products; (3) there was a substantial risk that Outset Medical would cease sales of the Tablo products pending FDA approval of additional indications; (4) Outset Medical lacked the sales team and process to execute on the ramp of Tablo sales; (5) as a result of the foregoing, Outset Medical’s revenue growth would be adversely impacted; and (6) as a result of the foregoing, defendants’ positive statements about Outset Medical’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you are a long-term stockholder of Outset Medical, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the lawsuit against Outset Medical about?

The lawsuit alleges that Outset Medical misled investors regarding their Tablo products.

What time period does the class action cover?

The class action covers the period from August 1, 2022, to August 7, 2024.

Who can participate in the investigation?

Long-term stockholders of Outset Medical can participate in the investigation.

How can I contact Bragar Eagel & Squire for more information?

You can email investigations@bespc.com or call (212) 355-4648 for inquiries.

Is there a cost to participate in the investigation?

There is no cost or obligation for stockholders to participate in the investigation.

Last updated: Dec 4, 2024